艾贝格司亭α与PEG-rhG-CSF预防局部晚期鼻咽癌患者诱导化疗序贯同步放化疗后中性粒细胞减少症的疗效与安全性OA

Objective To investigate the efficacy and safety of efbemalenograstim alfa versus polyethylene glycol recombinant human granulocyte colony-stimulating factor(PEG-rhG-CSF)in preventing neutropenia(CIN)after induction chemotherapy(IC)and sequential concurrent chemoradiotherapy(CCRT)for patients with locally advanced nasopharyngeal carcinoma(LA-NPC).Methods Clinical data of 204 LA-NPC patients in stage Ⅲ-ⅣA were retrospectively analyzed.Patients were divided into efbemalenograstim alfa group(n=78)or PEG-rhG-CSF group(n=126)according to the medication regimen.The efbemalenograstim alfa group received subcutaneous injection of Efbemalenograstim Alfa Injection on the basis of standard therapeutic regimen,while the PEG-rhG-CSF group received subcutaneous injection of PEG-rhG-CSF Injection on the basis of standard therapeutic regimen.Propensity score matching(PSM)was used to match confounding factors at a 1:1 ratio.After matching,The duration and incidence rate of grade 3-4 CIN,incidence rate of grade 4 CIN,incidence rate of febrile neutropenia(FN)during the 3 cycles of IC and 3 cycles of sequential CCRT were compared between patients of the two groups,occurrence of bone pain,adverse reactions,and chemotherapy completion status were recorded in both groups.Results After PSM,63 pairs of patients were successfully matched.During the three IC cycles and three sequential CCRT cycles,there was no statistically significant difference in the incidence rates of grade 3-4 CIN,grade 4 CIN,or FN between the two groups(P>0.05).The duration of grade 3-4 CIN in the efbemalenograstim alfa group was shorter,the total incidence rate of bone pain was lower,and the severity of bone pain was milder than that in the PEG-rhG-CSF group(P<0.05).The completion rate was 100%in both groups during the three IC cycles and three sequential CCRT cycles.There was no statistically significant difference in the incidence rate of adverse reactions,chemotherapy delay rate,or number of days of chemotherapy delay between the two groups(P>0.05).Conclusion Efbemalenograstim alfa is non-inferior to PEG-rhG-CSF in preventing CIN after IC and sequential CCRT in LA-NPC patients.However,it can more effectively shorten the duration of myelosuppression,reduce the severity of bone pain,and decrease the risk of bone pain,with a favorable safety profile.